Anthropic's Long-Term Benefit Trust, the body meant to keep the company's public-benefit mission from being swallowed by commercial pressure, has a new member. Christopher Stubbs, an experimental physicist and Harvard's Dean of Science from 2018 to 2024, joins at a moment when the Trust's role is about to be tested by a stock market listing.
Stubbs brings a scientist's record rather than a technologist's. In 1998, as part of the High-Z Supernova Search Team, he helped discover that the universe's expansion is accelerating, work later recognised with the Breakthrough Prize in Fundamental Physics. He was the first project scientist for what is now the Vera C. Rubin Observatory, which began a 10-year survey of the southern sky in June. He is a member of JASON, the independent group of scientists that has advised the US government on defence and technology since 1960, and has advised on national security and arms control. More recently he has written about keeping AI-assisted research reproducible when models can give different answers to the same question, and he says he uses AI tools in his research every day.
He joins Neil Buddy Shah, who chairs the Trust, the national security expert Richard Fontaine and former Federal Reserve Chair Ben Bernanke, and is its first physicist. Anthropic says the trustees are independent of management and investors.
The Trust's powers are what make the appointment matter. As Anthropic describes it, the Trust can appoint a majority of the company's board, and trustees advise the board and leadership on major decisions, especially those involving risk and the social effects of AI. Anthropic's recent S-1 filing confirms that the Trust elects a majority of the board after a listing, alongside a single share that gives the seven co-founders 50.1% of the vote. In the same week, Anthropic published its first Public Benefit Report, with the trustees' assessment of progress against five charter pillars, and pledged shares to a new public benefit fund.
A scientist who has written on reproducibility is a sensible choice for a company whose models are increasingly used in research. But the Trust's value will be judged by its use of power, not by the quality of its members. The announcement describes advice and appointments, not any case of the Trust overruling management, and the arrival of public shareholders will add new pressure on the board it oversees. How the Trust handles that, and how openly it reports disagreements, is the test that matters.